AnaptysBio (NASDAQ:ANAB) Price Target Increased to $90.00 by Analysts at Guggenheim

AnaptysBio (NASDAQ:ANAB) had its price objective raised by Guggenheim from $75.00 to $90.00 in a research note released on Monday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Several other equities analysts have also recently commented on ANAB. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a report on Wednesday, August 14th. JPMorgan Chase & Co. lifted their price objective on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Truist Financial upped their target price on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Finally, Wedbush reiterated an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $54.64.

AnaptysBio Trading Up 1.1 %

Shares of AnaptysBio stock opened at $35.37 on Monday. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $41.31. The stock has a 50-day moving average price of $35.46 and a 200 day moving average price of $29.49. The company has a market cap of $966.27 million, a P/E ratio of -5.76 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. On average, equities analysts forecast that AnaptysBio will post -6.84 earnings per share for the current fiscal year.

Insider Activity at AnaptysBio

In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the sale, the chief financial officer now owns 4,744 shares of the company’s stock, valued at $189,333.04. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The shares were purchased at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the acquisition, the insider now directly owns 7,794,996 shares of the company’s stock, valued at $284,517,354. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the sale, the chief financial officer now owns 4,744 shares of the company’s stock, valued at $189,333.04. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,440 shares of company stock valued at $892,936. Corporate insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

A number of institutional investors have recently made changes to their positions in the business. nVerses Capital LLC boosted its stake in AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the period. Duncan Williams Asset Management LLC acquired a new position in shares of AnaptysBio during the third quarter worth approximately $282,000. SG Americas Securities LLC bought a new stake in shares of AnaptysBio in the third quarter valued at approximately $405,000. Algert Global LLC grew its stake in shares of AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after acquiring an additional 1,078 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. increased its position in AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after acquiring an additional 1,265,891 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.